Annovis Bio, Inc. (NYSE: ANVS)
$6.7650
-0.0250 ( -1.24% ) 84.0K
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Market Data
Open
$6.7650
Previous close
$6.7900
Volume
84.0K
Market cap
$93.68M
Day range
$6.7500 - $7.0200
52 week range
$4.5300 - $22.4900
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 13 | Mar 22, 2024 |
| 8-k | 8K-related | 14 | Mar 21, 2024 |
| 8-k | 8K-related | 14 | Mar 20, 2024 |
| 8-k | 8K-related | 13 | Mar 20, 2024 |
| 8-k | 8K-related | 15 | Mar 15, 2024 |
| 4/a | Other | 1 | Nov 22, 2023 |
| 4/a | Other | 1 | Nov 22, 2023 |
| 4/a | Other | 1 | Nov 22, 2023 |
| 4/a | Other | 1 | Nov 22, 2023 |
| 4/a | Other | 1 | Nov 22, 2023 |